Sharemaestro company-news research for CVRx Inc (CVRX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest CVRX news and sentiment
CVRx Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early negative news score
22 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone21/100
→
Published 30-day score41/100
Latest source headline
CVRx stock gained 3.85 percent ahead of Barostim data
AD HOC NEWS · 07 Oct 2026 05:24
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
22 current stories are mapped specifically to CVRX.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.393.
Confidence is 28/100, below the threshold for a firm score.
41/100
News scoreEarly negative news score
28/100
Confidencethin evidence
100%/100
Company news22 company stories
95/100
Story agreement5/100 difference
News history
Daily score and story count over 30 days
12 Sep27 Sep11 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence8
0.393 after freshness weightingSource breadth80
4 independent publishersCompany relevance100
share tied directly to this companyFreshness20
recency-weighted evidenceAgreement95
how closely stories agreePublisher mix68
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks21 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202642USD 1.58+1.9%
02 Oct 202639USD 1.55-42.6%
25 Sep 202642USD 2.7-11.2%
18 Sep 202643USD 3.04+5.6%
11 Sep 202642USD 2.88-5.6%
04 Sep 202638USD 3.05+3.4%
28 Aug 202636USD 2.95+3.9%
21 Aug 202633USD 2.84-7.8%
Provisional evidence
News subjects
What is shaping the score
Market update4910 stories · 45%
Earnings504 stories · 18%
Analyst action493 stories · 14%
Regulatory and legal192 stories · 9%
Deals and strategy231 stories · 5%
Guidance241 stories · 5%
Balance sheet551 stories · 5%
Source mix
Where the evidence comes from
Stock Titan233 stories · 14%
Moomoo493 stories · 14%
GlobeNewswire292 stories · 9%
AD HOC NEWS422 stories · 9%
Pluang151 stories · 5%
Finimize551 stories · 5%
Quiver Quantitative461 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences17Financial Markets11Finance11Earnings7IPO2Mergers And Acquisitions1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
15 May50 neutral11 Oct 10:07
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 10:07 | 42 | +2 | 26/100 (-4) | 22 (0) | Provisional |
| 07 Oct 23:59 | 40 | +3 | 30/100 (-7) | 22 (-1) | Provisional |
| 03 Oct 23:59 | 37 | -2 | 37/100 (+2) | 23 (+2) | Provisional |
| 02 Oct 23:59 | 39 | -6 | 35/100 (+9) | 21 (0) | Provisional |
| 30 Sep 23:59 | 45 | +1 | 26/100 (-1) | 21 (+1) | Provisional |
| 29 Sep 23:59 | 44 | +1 | 27/100 (-3) | 20 (+1) | Provisional |
| 27 Sep 23:59 | 43 | +2 | 30/100 (-5) | 19 (-1) | Provisional |
| 24 Sep 23:59 | 41 | -4 | 35/100 (+7) | 20 (-4) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 22 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal2 stories
60.0%0.0%
Deals and strategy1 story
32.3%0.0%
Guidance1 story
7.7%0.0%
Each side uses the same scale: 0–60.0% of the retained directional evidence.
Where the influence comes from
42.3%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
CVRx stock gained 3.85 percent ahead of Barostim data
CVRx stock saw a 3.85% gain, closing at USD 1.62, in anticipation of Barostim data presentations at the Heart Failure Society of America meeting starting October 9, 2026. The company reported Q2 2026 revenue of USD 15.71 million, exceeding consensus, but still posted a diluted EPS loss of…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx stock saw a 3.85% gain, closing at USD 1.62, in anticipation of Barostim data presentations at the Heart Failure Society of America meeting starting October 9, 2026. The company reported Q2 2026 revenue of USD 15.71 million, exceeding consensus, but still posted a diluted EPS loss of USD 0.53. Analysts maintain a Hold consensus with an average price target significantly above the current stock price, reflecting both Barostim's potential and execution risks.
- Published
- 07 Oct 2026 05:24
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 13D/A CVRx For: 2 October By Investing.com
This article from Investing.com announces the filing of Form 13D/A for CVRx on October 2nd. It is a brief, news-focused piece, typical of a financial news wire service. The content is essentially a headline repeated within the body.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article from Investing.com announces the filing of Form 13D/A for CVRx on October 2nd. It is a brief, news-focused piece, typical of a financial news wire service. The content is essentially a headline repeated within the body.
- Published
- 03 Oct 2026 03:59
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
23/100 tone
Deals and strategy
Share sales take a holder below 5% ownership of CVRx (CVRX).
Jorey Chernett has reduced his stake in CVRx (CVRX) to approximately 0.62% of the common stock as of October 2, 2026, after selling shares. This action, described as an "exit filing," means he no longer beneficially owns more than 5% of the company's outstanding shares. Chernett's decisio…
32.3% of directional evidence
High story strength
Scoring detailsDirect company coverage
Jorey Chernett has reduced his stake in CVRx (CVRX) to approximately 0.62% of the common stock as of October 2, 2026, after selling shares. This action, described as an "exit filing," means he no longer beneficially owns more than 5% of the company's outstanding shares. Chernett's decision to sell shares stemmed from a difference of opinion with CVRx management regarding the company's strategic direction.
- Published
- 03 Oct 2026 01:38
- News subject
- Deals and strategy
- Why this score
- Missed expectations, Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 65/100
- 30-day weight
- 32.3% of directional evidence · 8.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial Markets
15/100 tone
Hagens Berman has initiated an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand concerning potential false claims and kickbacks related to its Barostim heart failure device. This comes after CVRx reported significant operational problems, incl…
42.3% of directional evidence
High story strength
Scoring detailsDirect company coverage
Hagens Berman has initiated an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand concerning potential false claims and kickbacks related to its Barostim heart failure device. This comes after CVRx reported significant operational problems, including reduced revenue guidance, sales force disruptions, and a decline in Medicare Advantage approvals, leading to a 59% stock plunge and the termination of its Chief Revenue Officer. The investigation will examine whether CVRx misled investors and if the DOJ probe is connected to the CRO's firing.
- Published
- 02 Oct 2026 01:53
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction, Guidance cut, Operating deterioration
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 73/100
- 30-day weight
- 42.3% of directional evidence · 9.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
$CVRX stock is down 33% today. Here's what we see in our data.
CVRX stock experienced a 33% drop today, with approximately $7.46 million in trading volume. Insider trading data shows the Chief Operating Officer, Brent Binkowski, made both purchases and sales of CVRX stock in the last six months. Institutional activity indicates a mixed sentiment, wit…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRX stock experienced a 33% drop today, with approximately $7.46 million in trading volume. Insider trading data shows the Chief Operating Officer, Brent Binkowski, made both purchases and sales of CVRX stock in the last six months. Institutional activity indicates a mixed sentiment, with 39 investors increasing and 43 decreasing their positions in Q2 2026, including significant moves by BALYASNY ASSET MANAGEMENT L.P. and ROYAL BANK OF CANADA.
- Published
- 30 Sep 2026 19:27
- News subject
- Market update
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
New registry analyses of a heart failure device are scheduled for a late-breaking session.
CVRx (NASDAQ: CVRX) announced its Barostim device will be featured in eight events, including late-breaking clinical data and podium sessions, at the HFSA Annual Scientific Meeting 2026. New analyses from the REBALANCE Registry, evaluating Barostim’s safety and benefits in commercial use,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx (NASDAQ: CVRX) announced its Barostim device will be featured in eight events, including late-breaking clinical data and podium sessions, at the HFSA Annual Scientific Meeting 2026. New analyses from the REBALANCE Registry, evaluating Barostim’s safety and benefits in commercial use, will be presented by Dr. Dmitry Yaranov. Additionally, Dr. Javed Butler will present real-world evidence on Baroreflex Activation Therapy in heart failure with mid-range ejection fraction (HFmrEF), focusing on reduced hospitalization burden.
- Published
- 29 Sep 2026 20:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
CVRx Announces Late-Breaking Data and New Clinical Evidence
CVRx, Inc. announced the schedule of scientific presentations for its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will feature late-breaking clinical data from the REBALANCE Registry and new real-world evidence on Barostim for…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx, Inc. announced the schedule of scientific presentations for its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will feature late-breaking clinical data from the REBALANCE Registry and new real-world evidence on Barostim for heart failure with preserved ejection fraction (HFmrEF), alongside several other sessions and two sponsored symposia. This highlights Barostim's role in the heart failure care continuum and provides new insights across patient populations and clinical outcomes.
- Published
- 29 Sep 2026 16:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
CVRX Oct 2026 5.000 put (CVRX261016P00005000) Stock Price, News, Quote & History
This page provides financial information for the CVRX Oct 2026 5.000 put option, identified by the ticker CVRX261016P00005000. It displays the current price, historical data, and key metrics such as previous close, open, bid, ask, strike price, and expiration date. The page also includes …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides financial information for the CVRX Oct 2026 5.000 put option, identified by the ticker CVRX261016P00005000. It displays the current price, historical data, and key metrics such as previous close, open, bid, ask, strike price, and expiration date. The page also includes chart data and volume information for the option.
- Published
- 27 Sep 2026 10:50
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
29/100 tone
Hagens Berman, a national shareholder rights litigation firm, has launched an investigation into CVRx Inc. (NASDAQ: CVRX) for potential federal securities law violations. This follows a 59% stock drop after disclosures of a DOJ Civil Investigative Demand, significant revenue guidance cuts…
17.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Hagens Berman, a national shareholder rights litigation firm, has launched an investigation into CVRx Inc. (NASDAQ: CVRX) for potential federal securities law violations. This follows a 59% stock drop after disclosures of a DOJ Civil Investigative Demand, significant revenue guidance cuts, sales force issues, and the sudden termination of the company's Chief Revenue Officer. The firm is encouraging investors with substantial losses to contact them to evaluate their legal options.
- Published
- 24 Sep 2026 07:18
- News subject
- Regulatory and legal
- Why this score
- Negative market reaction, Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 17.7% of directional evidence · 17.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
EarningsNot used in direction
CVRx names John Landry as CFO
CVRx has appointed John Landry as its new CFO, effective October 12, as the company faces pressure to improve commercial performance of its Barostim heart failure device. Landry, who previously served as CFO for Nyxoah and Vapotherm, joins CVRx after an activist investor called for the co…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx has appointed John Landry as its new CFO, effective October 12, as the company faces pressure to improve commercial performance of its Barostim heart failure device. Landry, who previously served as CFO for Nyxoah and Vapotherm, joins CVRx after an activist investor called for the company's sale due to repeated revenue forecast cuts and perceived underperformance. The company's CEO, Kevin Hykes, expressed confidence in Landry's experience in high-growth medical device companies to navigate this critical period.
- Published
- 24 Sep 2026 03:51
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinanceLife Sciences
—Unscored
EarningsNot used in direction
CVRx Inc. (CVRX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for CVRx Inc. (CVRX) on NASDAQ, showing a current price of $2.70 with a 6.72% increase. It notes that there is no current information on analyst ratings or earnings for the company. The page also offers various trading resources and promotio…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides live stock quotes and charts for CVRx Inc. (CVRX) on NASDAQ, showing a current price of $2.70 with a 6.72% increase. It notes that there is no current information on analyst ratings or earnings for the company. The page also offers various trading resources and promotional content for stock trading tools.
- Published
- 24 Sep 2026 03:51
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
—Unscored
Analyst actionNot used in direction
Lake Street Downgrades CVRx Inc(CVRX.US) to Hold Rating, Cuts Target Price to $3.5
Lake Street has downgraded CVRx Inc (CVRX.US) from a Buy rating to a Hold rating. The firm also significantly reduced its price target for CVRx from $18 to $3.5. This comes after CVRx Inc. announced an underwritten public offering of 11,000,000 shares of its common stock.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Lake Street has downgraded CVRx Inc (CVRX.US) from a Buy rating to a Hold rating. The firm also significantly reduced its price target for CVRx from $18 to $3.5. This comes after CVRx Inc. announced an underwritten public offering of 11,000,000 shares of its common stock.
- Published
- 23 Sep 2026 10:50
- News subject
- Analyst action
- Why this score
- Analyst downgrade, Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
EarningsNot used in direction
CVRx, Inc. (CVRX) stock price, news, quote and history
This page provides a comprehensive overview of CVRx, Inc. (CVRX) stock, including its current price, historical data, financial statistics, and analyst ratings. CVRx, Inc. is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its primary p…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides a comprehensive overview of CVRx, Inc. (CVRX) stock, including its current price, historical data, financial statistics, and analyst ratings. CVRx, Inc. is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its primary product being Barostim. The company's financial performance shows a negative profit margin and EPS, with analysts providing an average target price of $4.58.
- Published
- 23 Sep 2026 03:54
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Hold Rating
Craig-Hallum has reiterated a Hold rating for CVRx Inc (CVRX.US). This suggests the firm believes the stock will perform in line with the broader market and advises investors to maintain their current positions.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Craig-Hallum has reiterated a Hold rating for CVRx Inc (CVRX.US). This suggests the firm believes the stock will perform in line with the broader market and advises investors to maintain their current positions.
- Published
- 23 Sep 2026 00:24
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Finance
—Unscored
Market updateNot used in direction
CVRx taps new CFO from Nyxoah
CVRx has appointed John Landry as its new Chief Financial Officer, effective October 12, following the resignation of Jared Oasheim. Landry joins CVRx from Nyxoah, bringing extensive experience in financing high-growth medical device companies. His appointment comes amidst other executive…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx has appointed John Landry as its new Chief Financial Officer, effective October 12, following the resignation of Jared Oasheim. Landry joins CVRx from Nyxoah, bringing extensive experience in financing high-growth medical device companies. His appointment comes amidst other executive departures, a federal investigation into marketing practices, and activist investor pressure for the company to consider a sale.
- Published
- 22 Sep 2026 22:47
- News subject
- Market update
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceIPOLife Sciences
—Unscored
Analyst actionNot used in direction
Piper Sandler Downgrades CVRx Inc(CVRX.US) to Hold Rating, Cuts Target Price to $4
Piper Sandler has downgraded CVRx Inc (CVRX.US) from an Overweight to a Hold rating. The firm also significantly cut its price target for CVRx from $20 to $4. This downgrade and price target reduction suggest a more cautious outlook on the company's stock by Piper Sandler.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Piper Sandler has downgraded CVRx Inc (CVRX.US) from an Overweight to a Hold rating. The firm also significantly cut its price target for CVRx from $20 to $4. This downgrade and price target reduction suggest a more cautious outlook on the company's stock by Piper Sandler.
- Published
- 22 Sep 2026 16:25
- News subject
- Analyst action
- Why this score
- Analyst downgrade
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Balance sheetNot used in direction
CVRx Faces Fresh Pressure as Activist Pushes a Sale
CVRx, a medical device company, is facing pressure from an activist investor pushing for a sale, amidst modest revenue growth and continued cash burn. The company's future hinges on the success of its BENEFIT-HF clinical trial, broader payer coverage, and strategic initiatives, despite hi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx, a medical device company, is facing pressure from an activist investor pushing for a sale, amidst modest revenue growth and continued cash burn. The company's future hinges on the success of its BENEFIT-HF clinical trial, broader payer coverage, and strategic initiatives, despite high gross margins on its Barostim product. While the stock trades at a discount, investors are weighing the potential for M&A or clinical success against ongoing profitability and execution risks.
- Published
- 22 Sep 2026 06:47
- News subject
- Balance sheet
- Why this score
- Operating growth
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife SciencesMergers And Acquisitions
—Unscored
Market updateNot used in direction
CVRx, Inc. Appoints John Landry as Chief Financial Officer, Effective October 12, 2026
CVRx, Inc. has announced the appointment of John Landry as its new Chief Financial Officer, effective October 12, 2026. Landry will succeed Jared Oasheim, who will remain with the company for a transition period. Mr. Landry brings over two decades of financial leadership experience in the…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx, Inc. has announced the appointment of John Landry as its new Chief Financial Officer, effective October 12, 2026. Landry will succeed Jared Oasheim, who will remain with the company for a transition period. Mr. Landry brings over two decades of financial leadership experience in the medical device industry, having previously served as CFO of Nyxoah SA and Senior Vice President and CFO at Vapotherm, Inc., where he led its IPO.
- Published
- 22 Sep 2026 06:47
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 4 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
CVRx appoints John Landry as chief financial officer By Investing.com
CVRx Inc. has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, currently CFO of Nyxoah SA, will join CVRx on October 12, 2026, and officially take over after the company files its Q3 2026 Form 10-Q. CVRx develops neuromodulatio…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx Inc. has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, currently CFO of Nyxoah SA, will join CVRx on October 12, 2026, and officially take over after the company files its Q3 2026 Form 10-Q. CVRx develops neuromodulation solutions for cardiovascular diseases, with its Barostim product approved for heart failure patients.
- Published
- 22 Sep 2026 06:47
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
After leading a medical-device company's stock-market debut, John Landry will join CVRx.
CVRx (NASDAQ: CVRX) has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, an experienced medtech finance executive, will join on October 12, 2026, and officially assume the CFO role after the company files its Q3 2026 Form 10-Q.…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CVRx (NASDAQ: CVRX) has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, an experienced medtech finance executive, will join on October 12, 2026, and officially assume the CFO role after the company files its Q3 2026 Form 10-Q. He previously led Nyxoah SA as CFO and oversaw Vapotherm's IPO and financial infrastructure development.
- Published
- 22 Sep 2026 03:51
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceIPOLife Sciences
—Unscored
Market updateNot used in direction
CVRx Names New Chief Financial Officer
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 20:23
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
24/100 tone
7.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 18 Sep 2026 15:44
- News subject
- Guidance
- Why this score
- Guidance cut
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 55/100
- 30-day weight
- 7.7% of directional evidence · 22.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
CVRX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 105 older CVRX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to CVRX, but the headline and available text are not mainly about CVRx Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of CVRX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.